Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Pulmonary Vascular Fibroblasts As Key Drivers Of Vascular Remodeling in Pulmonary Arterial Hypertension
FY 2019-20
Summary
" Pulmonary hypertension (PH) is a clinical syndrome defined by elevated pressure in the pulmonary arteries. A subset of PH, termed pulmonary arterial hypertension (PAH), is a disease localized to the lung vasculature. PAH is characterized by remodelling and immunological infiltration within the pulmonary vasculature, often leading to right-sided heart failure. Although a relatively rare condition, the problems associated with PAH can lead to 5-year mortality rates as high as 60%. Available therapies focus on pulmonary vasodilation, and while useful, these drugs have not yielded the benefits that were initially desired. As such, researchers are investigating other therapeutic modalities, focusing primarily on the immunological aspects of this disease. My project seeks to further investigate the immunological problems associated with PAH. Fibroblasts, a major cell type found in the outer layer of the pulmonary vessels, are known to be dysfunctional in many forms of PAH. It is believed that these cells are responsible for the recruitment of inflammatory molecules and immune cells to the vessel wall in PAH. My project will involve investigating the response of these fibroblasts to high-mobility group box-1 (HMGB1), an important signalling molecule known to propagate many inflammatory responses in the body. I hypothesize that this molecule is highly important in contributing to fibroblast dysfunction and pulmonary vasculature inflammation in PAH. If successful, this project will help define HMGB1 as an early driver of vascular fibroblast dysfunction in PAH. Such work would help deepen our understanding of the pathogenesis of this disease, and point to potential therapeutic targets (HMGB1, fibroblasts) in the treatment of this life-limiting condition. "
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428733
Name
Chi Leon
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pulmonary Vascular Fibroblasts As Key Drivers Of Vascular Remodeling in Pulmonary Arterial Hypertension
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Fibroblasts; Lung Physiology; Pulmonary Hypertension; Pulmonary Vascular Inflammation
Abstract
" Pulmonary hypertension (PH) is a clinical syndrome defined by elevated pressure in the pulmonary arteries. A subset of PH, termed pulmonary arterial hypertension (PAH), is a disease localized to the lung vasculature. PAH is characterized by remodelling and immunological infiltration within the pulmonary vasculature, often leading to right-sided heart failure. Although a relatively rare condition, the problems associated with PAH can lead to 5-year mortality rates as high as 60%. Available therapies focus on pulmonary vasodilation, and while useful, these drugs have not yielded the benefits that were initially desired. As such, researchers are investigating other therapeutic modalities, focusing primarily on the immunological aspects of this disease. My project seeks to further investigate the immunological problems associated with PAH. Fibroblasts, a major cell type found in the outer layer of the pulmonary vessels, are known to be dysfunctional in many forms of PAH. It is believed that these cells are responsible for the recruitment of inflammatory molecules and immune cells to the vessel wall in PAH. My project will involve investigating the response of these fibroblasts to high-mobility group box-1 (HMGB1), an important signalling molecule known to propagate many inflammatory responses in the body. I hypothesize that this molecule is highly important in contributing to fibroblast dysfunction and pulmonary vasculature inflammation in PAH. If successful, this project will help define HMGB1 as an early driver of vascular fibroblast dysfunction in PAH. Such work would help deepen our understanding of the pathogenesis of this disease, and point to potential therapeutic targets (HMGB1, fibroblasts) in the treatment of this life-limiting condition. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chi, Leon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~